Search

Your search keyword '"Li, Wende"' showing total 321 results
Start Over Author "Li, Wende"
321 results on '"Li, Wende"'

5. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

Author

He, Jingjing, Xiong, Xinxin, Yang, Han, Li, Dandan, Liu, Xuefei, Li, Shuo, Liao, Shuangye, Chen, Siyu, Wen, Xizhi, Yu, Kuai, Fu, Lingyi, Dong, Xingjun, Zhu, Kaiyu, Xia, Xiaojun, Kang, Tiebang, Bian, Chaochao, Li, Xiang, Liu, Haiping, Ding, Peirong, Zhang, Xiaoshi, Liu, Zhenjiang, Li, Wende, Zuo, Zhixiang, and Zhou, Penghui

Published
2022
Full Text
View/download PDF

11. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway

Author

Chen, Jiewen, primary, Xu, Qingji, additional, Liu, Dan, additional, Li, Xun, additional, Guo, Mingyan, additional, Chen, Xuehui, additional, Liao, Jianyou, additional, Lei, Rong, additional, Li, Wende, additional, Huang, Hongyan, additional, Saw, Phei Er, additional, Song, Erwei, additional, Yan, Xiyun, additional, and Nie, Yan, additional

Published
2023
Full Text
View/download PDF

14. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity

Author

Wang, Zining, Chen, Jiemin, Hu, Jie, Zhang, Hongxia, Xu, Feifei, He, Wenzhuo, Wang, Xiaojuan, Li, Mengyun, Lu, Wenhua, Zeng, Gucheng, Zhou, Penghui, Huang, Peng, Chen, Siyu, Li, Wende, Xia, Liang-ping, and Xia, Xiaojun

Subjects
Cancer treatment, Cancer -- Drug therapy, Cell death, Immunotherapy, Dendritic cells, Chromosomal proteins, Antibodies, Immune response, T cells, Biochemistry, Antineoplastic agents, Tumors, DNA, Genetic research, Cancer cells, Genes, DNA damage, Health care industry
Abstract

Checkpoint blockade antibodies have been approved as immunotherapy for multiple types of cancer, but the response rate and efficacy are still limited. There are few immunogenic cell death-inducing (ICD-inducing) drugs available that can kill cancer cells, enhance tumor immunogenicity, increase in vivo immune infiltration, and thereby boost a tumor response to immunotherapy. So far, the ICD markers have been identified as the few immunostimulating characteristics of dead cells, but whether the presence of such ICD markers on tumor cells translates into enhanced antitumor immunity in vivo is still being investigated. To identify anticancer drugs that could induce tumor cell death and boost T cell response, we performed drug screenings based on both an ICD reporter assay and a T cell activation assay. We showed that teniposide, a DNA topoisomerase II inhibitor, could induce high-mobility group box 1 (HMGB1) release and type I IFN signaling in tumor cells and that teniposide-treated tumor cells could activate antitumor T cell response both in vitro and in vivo. Mechanistically, teniposide induced tumor cell DNA damage and innate immune signaling, including NF-[kappa]B activation and stimulator of IFN genes-dependent (STING-dependent) type I IFN signaling, both of which contribute to the activation of dendritic cells and subsequent T cells. Furthermore, teniposide potentiated the antitumor efficacy of anti-PD1 in multiple types of mouse tumor models. Our findings showed that teniposide could trigger tumor immunogenicity and enabled a potential chemoimmunotherapeutic approach to potentiating the therapeutic efficacy of anti-PD1 immunotherapy., Introduction Cancer immunotherapy has become the major theme of cancer treatment regimens in the last few years, testifying to the genuine capability of the immune control of cancer (1, 2). [...]

Published
2019
Full Text
View/download PDF

18. Blocking the formation of radiation–induced breast cancer stem cells

Author

Wang, Yangyang, Li, Wende, Patel, Shalin S, Cong, Juan, Zhang, Nan, Sabbatino, Francesco, Liu, Xiaoyan, Qi, Yuan, Huang, Peigen, Lee, Hang, Taghian, Alphonse, Li, Jian-Jian, DeLeo, Albert B, Ferrone, Soldano, Epperly, Michael W, Ferrone, Cristina R, Ly, Amy, Brachtel, Elena F, and Wang, Xinhui

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Stem Cell Research - Nonembryonic - Non-Human, Breast Cancer, Cancer, Good Health and Well Being, Animals, Breast Neoplasms, Cell Line, Tumor, Female, Heterografts, Humans, Mammary Neoplasms, Experimental, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Recurrence, Local, Neoplasms, Radiation-Induced, Neoplastic Stem Cells, Radiation Tolerance, Radiotherapy, Adjuvant, Random Allocation, Transfection, Radiation, Cancer Stem Cells, NF-kappaB Stemness genes, Oncology and carcinogenesis
Abstract

The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer (BC) is to eliminate residual cancer cells, leading to better local tumor control and thus improving patient survival. However, radioresistance increases the risk of tumor recurrence and negatively affects survival. Recent evidence shows that breast cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced re-expression of the stemness genes. Here we show that in irradiation (IR)-treated mice bearing syngeneic mammary tumors, IR-induced stemness correlated with increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was blocked by targeting the NF-κB- stemness gene pathway with disulfiram (DSF)and Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes (DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome inhibitor, which, in turn, inhibits NF-κB activation. Treatment of mice with RT and DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy was associated with decreased stem cell properties (or stemness) in tumors. We expect that these results will spark clinical investigation of RT and DSF as a novel combinatorial treatment for breast cancer.

Published
2014

25. Supplementary Tables 1-4 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 5 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 3 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

29. Data from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table S1 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legends from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 6 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 4 from DGKA Mediates Resistance to PD-1 Blockade

Author

Fu, Lingyi, primary, Li, Sen, primary, Xiao, WeiWei, primary, Yu, Kuai, primary, Li, Shuo, primary, Yuan, Sujing, primary, Shen, Jianfei, primary, Dong, Xingjun, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Chen, Siyu, primary, Li, Wende, primary, You, Hua, primary, Xia, Xiaojun, primary, Kang, Tiebang, primary, Tan, Jing, primary, Chen, Gong, primary, Yang, An-Kui, primary, Gao, YuanHong, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Author

Zhang, Xiaomin, primary, Cheng, Limin, primary, Gao, Chengqi, primary, Chen, Jing, primary, Liao, Shuangye, primary, Zheng, Yongqiang, primary, Xu, Liping, primary, He, Jingjing, primary, Wang, Danyang, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Yan, Min, primary, Luan, Yi, primary, Chen, Siyu, primary, Chen, Likun, primary, Xia, Xiaojun, primary, Deng, Chunhao, primary, Chen, Guokai, primary, Li, Wende, primary, Liu, Zexian, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy

Author

Nie, Yan, primary, Huang, Hongyan, primary, Guo, Mingyan, primary, Chen, Jiewen, primary, Wu, Wei, primary, Li, Wende, primary, Xu, Xiaoding, primary, Lin, Xiaorong, primary, Fu, Wenkui, primary, Yao, Yandan, primary, Zheng, Fang, primary, Luo, Man-Li, primary, Saw, Phei Er, primary, Yao, Herui, primary, Song, Erwei, primary, and Hu, Hai, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 2 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Author

Zhang, Xiaomin, primary, Cheng, Limin, primary, Gao, Chengqi, primary, Chen, Jing, primary, Liao, Shuangye, primary, Zheng, Yongqiang, primary, Xu, Liping, primary, He, Jingjing, primary, Wang, Danyang, primary, Fang, Ziqian, primary, Zhang, Jianeng, primary, Yan, Min, primary, Luan, Yi, primary, Chen, Siyu, primary, Chen, Likun, primary, Xia, Xiaojun, primary, Deng, Chunhao, primary, Chen, Guokai, primary, Li, Wende, primary, Liu, Zexian, primary, and Zhou, Penghui, primary

Published
2023
Full Text
View/download PDF

40. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer

Author

Li, Senlin, primary, Chen, Siyu, additional, Dong, Zhihui, additional, Song, Xingdong, additional, Li, Xiuling, additional, Huang, Ziqi, additional, Li, Huiru, additional, Huang, Linzhuo, additional, Zhuang, Ganyuan, additional, Lan, Ran, additional, Guo, Mingyan, additional, Li, Wende, additional, Saw, Phei Er, additional, and Zhang, Lei, additional

Published
2023
Full Text
View/download PDF

43. Contributors

Author

Ačanski, Marijana, primary, Agama-Acevedo, Edith, additional, Ahmed, Mohamed A., additional, Akhtar, Saeed, additional, Alonso-Domínguez, Rosario, additional, Anyango, Joseph O., additional, Apea-Bah, Franklin B., additional, Arantes, Vanessa Cristina, additional, Arzani, Ahmad, additional, Aslam, Mohamad F., additional, Barrera, Gladys, additional, Beckett, Emma, additional, Bello-Pérez, Luis A., additional, Berry, Sarah E., additional, Beta, Trust, additional, Brandolini, Andrea, additional, Bunout, Daniel, additional, Campa-Mada, Alma C., additional, Campbell, Lydia, additional, Carvajal-Millan, Elizabeth, additional, Catzeddu, Pasquale, additional, Chiavaro, Emma, additional, Chuck Hernández, Cristina Elizabeth, additional, Coda, Rossana, additional, da Costa Rodrigues, Priscila, additional, da Rosa, Chaiane Aline, additional, de Barros Reis, Marise Auxiliadora, additional, de la Maza, Maria Pia, additional, Ellis, Peter R., additional, Erbakan, Ayşe Naciye, additional, Euston, Stephen R., additional, Franca, Adriana S., additional, González-Sálamo, Javier, additional, Guardado-Félix, Daniela, additional, Hajnal, Elizabet Janić, additional, Hayta, Mehmet, additional, Heredia-Olea, Erick, additional, Hernández-Borges, Javier, additional, Herrera-Herrera, Antonio V., additional, Hidalgo, Alyssa, additional, Hirsch, Sandra, additional, Hussain, Majid, additional, İşçimen, Elif Meltem, additional, Ismail, Tariq, additional, Izydorczyk, Marta S., additional, Jitngarmkusol, Siwaporn, additional, Kacmaz, Sibel, additional, Kumagai, Hitomi, additional, Latorraca, Márcia Queiroz, additional, Latunde-Dada, Gladys O., additional, Laux, Michele Cristiane, additional, Lazo-Vélez, Marco A., additional, Leiva, Laura, additional, Li, Wende, additional, Lima, Glaucia Cariello, additional, Lucock, Mark, additional, Maróstica Junior, Mário Roberto, additional, Marquez-Escalante, Jorge, additional, Mastilović, Jasna, additional, McMillan, Tricia, additional, Mert, Ilkem Demirkesen, additional, Mesci, Banu, additional, Montemurro, Marco, additional, Orčić, Dejan, additional, Paciulli, Maria, additional, Pasqualone, Antonella, additional, Pastor, Kristian, additional, Paz-Samaniego, Rita, additional, Perez-Carrillo, Esther, additional, Pontonio, Erica, additional, Pugliese, Alessandro, additional, Rascon-Chu, Agustín, additional, Recio-Rodríguez, José I., additional, Resende, Laís M., additional, Rinaldi, Massimiliano, additional, Rizzello, Carlo Giuseppe, additional, Rosell, Cristina M., additional, Sánchez-Aguadero, Natalia, additional, Serna-Saldivar, Sergio O., additional, Sharp, Paul A., additional, Shevkani, Khetan, additional, Singh, Narpinder, additional, Singh, Sandeep, additional, Singh, Prabhjeet, additional, Small, Darryl M., additional, Socas-Rodríguez, Bárbara, additional, Sotelo-Cruz, Norberto, additional, Stojceska, Valentina, additional, Sullivan, William R., additional, Tananuwong, Kanitha, additional, Taylor, John R.N., additional, Urade, Reiko, additional, Verni, Michela, additional, Virdi, Amardeep Singh, additional, Vujić, Djura, additional, Vuolo, Milena Morandi, additional, and Yıldız, Kübra, additional

Published
2019
Full Text
View/download PDF

48. Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Author

Zhang, Xiaomin, primary, Cheng, Limin, additional, Gao, Chengqi, additional, Chen, Jing, additional, Liao, Shuangye, additional, Zheng, Yongqiang, additional, Xu, Liping, additional, He, Jingjing, additional, Wang, Danyang, additional, Fang, Ziqian, additional, Zhang, Jianeng, additional, Yan, Min, additional, Luan, Yi, additional, Chen, Siyu, additional, Chen, Likun, additional, Xia, Xiaojun, additional, Deng, Chunhao, additional, Chen, Guokai, additional, Li, Wende, additional, Liu, Zexian, additional, and Zhou, Penghui, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results